Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, QLD 4072, Australia.
Biotechnol Adv. 2011 Nov-Dec;29(6):661-6. doi: 10.1016/j.biotechadv.2011.05.002. Epub 2011 May 14.
Red blood cell (RBC) transfusion is an essential practice in modern medicine, one that is entirely dependent on the availability of donor blood. Constraints in donor supply have led to proposals that transfusible RBC could be manufactured from stem cells. While it is possible to generate small amounts of RBC in vitro, very large numbers of cells are required to be of clinical significance. We explore the challenges facing large scale manufacture of RBC and technological developments required for such a scenario to be realised.
红细胞(RBC)输血是现代医学的一项基本实践,完全依赖于供体血液的供应。供体供应的限制导致了这样的提议,即可从干细胞中制造可输血的 RBC。虽然在体外生成少量 RBC 是可能的,但为了具有临床意义,需要大量的细胞。我们探讨了大规模制造 RBC 面临的挑战以及实现这种情况所需的技术发展。